Detail akcie Tiziana Life Sci Rg online

Business Summary: Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
Financial Summary: BRIEF: For the six months ended 30 June 2025, Tiziana Life Sciences Ltd - ADR revenues was not reported. Net loss increased 21% to $5.6M. Higher net loss reflects Research & Development of biotechnological and Pharmaceutica segment loss increase of 41% to $9.2M. Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.05.